Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Completed · Phase 2

Conditions studied: Type 2 Diabetes Mellitus

In brief

This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).

Key facts

Study ID

NCT00099333

Run by

AstraZeneca

People needed

49

Starts

2004-02-01

Expected to finish

2005-08-01

Last updated by the study team

2015-02-23

Who can join

Age: 35 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients have been treated with insulin for >=3 months up to 12 years.
• HbA1c <=10.5%.
• Body mass index (BMI) between 27 kg/m2 and 40 kg/m2.

You may not qualify if…

• Patients previously received exenatide or GLP-1 analogs.
• Patients have been treated for greater than 2 weeks with thiazolidinediones or alpha-glucosidase inhibitors within 3 months prior to screening.

Where it is running

• Research Site — Chula Vista, California, United States
• Research Site — Butte, Montana, United States
• Research Site — Portland, Oregon, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.